This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubin, L. J. Articles by Peter, R. H. Search for Related Content PubMed PubMed Citation Articles by Rubin, L. J. Articles by Peter, R. H.

Circulation, Vol 65, 1369-1373, Copyright © 1982 by American Heart Association

ARTICLES

The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure

LJ Rubin, F Handel and RH Peter

Hydralazine reduces pulmonary vascular resistance in patients with primary and secondary pulmonary hypertension, but the effects on right ventricular function of a change in resistance without a reduction in pulmonary arterial pressure are not known. We evaluated the hemodynamic effects of hydralazine, 50 mg, administered orally every 6 hours for 48 hours in 14 patients with right ventricular failure and pulmonary hypertension resulting from various causes. Hydralazine reduced mean right ventricular end-diastolic pressure from 17.4 +/- 5.6 to 11.6 +/- 5.3 mm Hg (p less than 0.001) and increased cardiac output and stroke volume by more than 40%. In nine patients who had no change in mean pulmonary arterial pressure after hydralazine, total pulmonary resistance decreased from 15.9 +/- 6.0 to 10.6 +/- 4.3 (p less than 0.001) and cardiac index increased from 2.07 +/- 0.51 to 2.97 +/- 0.91 (p less than 0.005). There was a close correlation between the reductions in total pulmonary resistance and right ventricular end- diastolic pressure (r = 0.73)). These data suggest that hydralazine can increase cardiac output and reduce right ventricular end-diastolic pressure even when pulmonary arterial pressure remains unchanged.

This article has been cited by other articles:

				M. A. Alpert, M. D. Concannon, B. Mukerji, and V. Mukerji Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations: Part I: Primary Pulmonary Hypertension Angiology, August 1, 1994; 45(8): 667 - 676. [Abstract] [PDF]

				M. PACKER Vasodilator Therapy for Primary Pulmonary Hypertension: Limitations and Hazards Ann Intern Med, August 1, 1985; 103(2): 258 - 270. [Abstract] [PDF]

				L. J. RUBIN, P. NICOD, L. D. HILLIS, and B. G. FIRTH Treatment of Primary Pulmonary Hypertension with Nifedipine: A Hemodynamic and Scintigraphic Evaluation Ann Intern Med, October 1, 1983; 99(4): 433 - 438. [Abstract] [PDF]